FMC

Investors need to pay close attention to DAKT stock based on the movements in the options market lately.

Evaluate FMC's (FMC) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

While the top- and bottom-line numbers for FMC (FMC) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

FMC NYSE: FMC reported second-quarter revenue of $841 million excluding India, below the low end of its guidance range, as cautious customer purchasing, unfavorable weather, low insect pressure and pricing pressure weighed on demand. However, adjusted EBITDA of $153 million exceeded the high end of management's guidance by 2%, aided by cost discipline and favorable quarter-specific items.

FMC Corporation (FMC) Q2 2026 Earnings Call Transcript

FMC's Q2 earnings beat estimates as cost gains offset weaker pricing and volumes. Revenues declined and 2026 sales guidance was cut.

Updates full-year outlook to reflect more challenging macro environment; Company continues to focus on execution of operational priorities Second Quarter 2026 Highlights Revenue of $867 million, down 17 percent versus Q2 2025 Revenue excluding India1 of $841 million, down 20 percent versus Q2 2025 (which included India) Organic revenue2 for the period declined 22 percent Consolidated GAAP net loss of $187 million, a decline of $253 million versus Q2 2025 Adjusted EBITDA of $153 million, down 26 percent versus Q2 2025 Consolidated GAAP net loss of $1.49 per diluted share, down $2.02 versus Q2 2025 Adjusted earnings per diluted share of $0.26, down 62% versus Q2 2025 GAAP cash from operations of $363 million, an increase of $297 million versus Q2 2025 Full-Year Outlook 1 Revenue excluding India lowered to a range of $3.50 billion to $3.70 billion, a decline of 7 percent at the midpoint versus 2025 Excluding 2025 India contributions, the 2026 outlook represents a decline at the midpoint of 5 percent Adjusted EBITDA lowered to a range of $620 million to $680 million, a decline of 23 percent at the midpoint Adjusted earnings per diluted share lowered to a range of $1.19 to $1.49, a decline of 55 percent at the midpoint Free cash flow, which now includes the upfront licensing payment for rimisoxafen of $200 million, increased to a range of $75 million to $225 million PHILADELPHIA, July 29, 2026 /PRNewswire/ -- FMC Corporation (NYSE: FMC) today reported second quarter 2026 revenue of $867 million, down 17 percent versus second quarter 2025.  Second quarter 2026 revenue, excluding India, was $841 million, down 20 percent versus second quarter 2025, which included India.

PHILADELPHIA, July 23, 2026 /PRNewswire/ -- FMC Corporation (NYSE: FMC) announced today that its board of directors declared a regular quarterly dividend of 8 cents per share, payable on October 15, 2026, to shareholders of record as of the close of business on September 30, 2026.    About FMC FMC Corporation is a global agricultural sciences company dedicated to helping growers produce food, feed, fiber and fuel for an expanding world population while adapting to a changing environment.

FMC (FMC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

FMC's first global dossier for rimisoxafen seeks U.S. approval for a dual-action herbicide aimed at tough broadleaf weeds in major crops.